BY SAUMYA JOSEPH: Too little sleep – or too much – can be tied to problems with blood sugar levels, not just in people with diabetes but also in people at high risk for developing the disease, a new study finds.
Irregular sleep schedules and poor sleep quality are known to be associated with poor blood sugar control in people who already have diabetes. In the current study, however, 73% of participants had “prediabetes” – meaning they weren’t yet diabetic but their blood sugar levels were almost in the diabetes range. The rest had recently been diagnosed with type 2 diabetes but hadn’t been treated yet.
“Don’t let the ‘pre’ fool you – prediabetes is a serious health condition,” public health officials warn on the website of the U.S. Centers for Disease Control and Prevention. “Prediabetes puts you at increased risk of developing type 2 diabetes, heart disease, and stroke.” (read more)
BY BENEDICT JEPHCOTE: A drug used to control type 2 diabetes can help reduce the progression of kidney disease or related death, researchers have said.
Dapagliflozin, an oral sodium glucose cotransporter 2 (SGLT2) inhibitor medication, reduced the risk of kidney function decline, end-stage renal disease and renal death in people with type 2 diabetes by 47 per cent.
The findings were part of the Dapagliflozin Effect on Cardiovascular Events Thrombolysis in Myocardial Infarction (DECLARE-TIMI 58) trial, which is the first trial to look at heart health outcomes among people with diabetes who are deemed at risk of developing Atherosclerotic Cardiovascular Disease (ASCVD). (read more)
BY JACK WOODFIELD: The development of type 1 diabetes has been delayed by at least a year in high-risk individuals by a new drug, according to new research.
The drug teplizumab works by changing the immune system’s white blood cells responsible for killing insulin-producing beta cells. It is the immune system’s attack on the beta cells that characterises type 1 diabetes.
The US study team reports this is the first time a medication has been able to delay the onset of type 1 diabetes.
Teplizumab treatment over 14 days decreased the rate of type 1 diabetes in those at high risk of the condition by half. (read more)
BY DLIFE: Although the use of continuous glucose monitors (CGMs) in clinical practice has drastically increased over the past five to six years, only about 25% of adolescents and young adults are using CGM, according to data from the T1D Exchange Clinic Registry of individuals with Type 1 diabetes.
CGMs can help children and their families monitor glucose levels in real time, alerting them to a possible need for treatment adjustments.
BY ANA SANDOIU: … Previous research has pointed to a connection between periodontitis — a chronic condition that affects the gums and bones that support the teeth — and diabetes.
The latter is a major risk factor for the former, with data showing that people with diabetes are three times more likely to develop periodontitis.
Also, the risk of mortality from ischemic heart disease combined with diabetes-related kidney complications is three times higher in people who have both diabetes and severe periodontitis, compared with people who only have diabetes. (read more)